These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 33531370)

  • 1. Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
    Boshuizen J; Pencheva N; Krijgsman O; Altimari DD; Castro PG; de Bruijn B; Ligtenberg MA; Gresnigt-Van den Heuvel E; Vredevoogd DW; Song JY; Visser N; Apriamashvili G; Janmaat ML; Plantinga TS; Franken P; Houtkamp M; Lingnau A; Jure-Kunkel M; Peeper DS
    Cancer Res; 2021 Apr; 81(7):1775-1787. PubMed ID: 33531370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
    Koopman LA; Terp MG; Zom GG; Janmaat ML; Jacobsen K; Gresnigt-van den Heuvel E; Brandhorst M; Forssmann U; de Bree F; Pencheva N; Lingnau A; Zipeto MA; Parren PW; Breij EC; Ditzel HJ
    JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31600169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
    Boshuizen J; Koopman LA; Krijgsman O; Shahrabi A; van den Heuvel EG; Ligtenberg MA; Vredevoogd DW; Kemper K; Kuilman T; Song JY; Pencheva N; Mortensen JT; Foppen MG; Rozeman EA; Blank CU; Janmaat ML; Satijn D; Breij ECW; Peeper DS; Parren PWHI
    Nat Med; 2018 Feb; 24(2):203-212. PubMed ID: 29334371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC.
    Konen JM; Rodriguez BL; Padhye A; Ochieng JK; Gibson L; Diao L; Fowlkes NW; Fradette JJ; Peng DH; Cardnell RJ; Kovacs JJ; Wang J; Byers LA; Gibbons DL
    Cancer Res; 2021 Mar; 81(5):1398-1412. PubMed ID: 33402388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.
    Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH
    Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axl and Mertk Receptors Cooperate to Promote Breast Cancer Progression by Combined Oncogenic Signaling and Evasion of Host Antitumor Immunity.
    Davra V; Kumar S; Geng K; Calianese D; Mehta D; Gadiyar V; Kasikara C; Lahey KC; Chang YJ; Wichroski M; Gao C; De Lorenzo MS; Kotenko SV; Bergsbaken T; Mishra PK; Gause WC; Quigley M; Spires TE; Birge RB
    Cancer Res; 2021 Feb; 81(3):698-712. PubMed ID: 33239426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting AXL and the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Melanoma.
    Flem-Karlsen K; McFadden E; Omar N; Haugen MH; Øy GF; Ryder T; Gullestad HP; Hermann R; Mælandsmo GM; Flørenes VA
    Mol Cancer Ther; 2020 Mar; 19(3):895-905. PubMed ID: 31871265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1α levels.
    Goyette MA; Elkholi IE; Apcher C; Kuasne H; Rothlin CV; Muller WJ; Richard DE; Park M; Gratton JP; Côté JF
    Proc Natl Acad Sci U S A; 2021 Jul; 118(29):. PubMed ID: 34266948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
    Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma.
    Van Renterghem B; Wozniak A; Castro PG; Franken P; Pencheva N; Sciot R; Schöffski P
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and validation of Axl-targeted monoclonal antibody probe for microPET imaging in human lung cancer xenograft.
    Liu S; Li D; Guo J; Canale N; Li X; Liu R; Krasnoperov V; Gill PS; Conti PS; Shan H; Li Z
    Mol Pharm; 2014 Nov; 11(11):3974-9. PubMed ID: 24978094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity.
    Terry S; Abdou A; Engelsen AST; Buart S; Dessen P; Corgnac S; Collares D; Meurice G; Gausdal G; Baud V; Saintigny P; Lorens JB; Thiery JP; Mami-Chouaib F; Chouaib S
    Cancer Immunol Res; 2019 Nov; 7(11):1789-1802. PubMed ID: 31488404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
    Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG
    Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
    Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
    Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.
    Ludwig KF; Du W; Sorrelle NB; Wnuk-Lipinska K; Topalovski M; Toombs JE; Cruz VH; Yabuuchi S; Rajeshkumar NV; Maitra A; Lorens JB; Brekken RA
    Cancer Res; 2018 Jan; 78(1):246-255. PubMed ID: 29180468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
    Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H
    Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of the phenylpyrazolo[3,4-
    Lee HJ; Pham PC; Pei H; Lim B; Hyun SY; Baek B; Kim B; Kim Y; Kim MH; Kang NW; Min HY; Kim DD; Lee J; Lee HY
    Theranostics; 2021; 11(4):1918-1936. PubMed ID: 33408789
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.